Intraprocedural thrombotic events

Jump to navigation Jump to search

WikiDoc Resources for Intraprocedural thrombotic events

Articles

Most recent articles on Intraprocedural thrombotic events

Most cited articles on Intraprocedural thrombotic events

Review articles on Intraprocedural thrombotic events

Articles on Intraprocedural thrombotic events in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Intraprocedural thrombotic events

Images of Intraprocedural thrombotic events

Photos of Intraprocedural thrombotic events

Podcasts & MP3s on Intraprocedural thrombotic events

Videos on Intraprocedural thrombotic events

Evidence Based Medicine

Cochrane Collaboration on Intraprocedural thrombotic events

Bandolier on Intraprocedural thrombotic events

TRIP on Intraprocedural thrombotic events

Clinical Trials

Ongoing Trials on Intraprocedural thrombotic events at Clinical Trials.gov

Trial results on Intraprocedural thrombotic events

Clinical Trials on Intraprocedural thrombotic events at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Intraprocedural thrombotic events

NICE Guidance on Intraprocedural thrombotic events

NHS PRODIGY Guidance

FDA on Intraprocedural thrombotic events

CDC on Intraprocedural thrombotic events

Books

Books on Intraprocedural thrombotic events

News

Intraprocedural thrombotic events in the news

Be alerted to news on Intraprocedural thrombotic events

News trends on Intraprocedural thrombotic events

Commentary

Blogs on Intraprocedural thrombotic events

Definitions

Definitions of Intraprocedural thrombotic events

Patient Resources / Community

Patient resources on Intraprocedural thrombotic events

Discussion groups on Intraprocedural thrombotic events

Patient Handouts on Intraprocedural thrombotic events

Directions to Hospitals Treating Intraprocedural thrombotic events

Risk calculators and risk factors for Intraprocedural thrombotic events

Healthcare Provider Resources

Symptoms of Intraprocedural thrombotic events

Causes & Risk Factors for Intraprocedural thrombotic events

Diagnostic studies for Intraprocedural thrombotic events

Treatment of Intraprocedural thrombotic events

Continuing Medical Education (CME)

CME Programs on Intraprocedural thrombotic events

International

Intraprocedural thrombotic events en Espanol

Intraprocedural thrombotic events en Francais

Business

Intraprocedural thrombotic events in the Marketplace

Patents on Intraprocedural thrombotic events

Experimental / Informatics

List of terms related to Intraprocedural thrombotic events

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: IPTE

Overview

Intraprocedural thrombotic events (IPTE) are a rare group of acute ischemic complications that occur during percutaneous coronary interventions (PCI). Although by definition IPTE should occur before the end of the PCI procedure; it can come about before or after stent-placement during PCI. In contrast to other complications that might occur before or after PCI, IPTE has recently been recognized as a special category of complications that include distinctive risk factors and associated patient and procedural characteristics. Most importantly, IPTE comprises a unique predictor of periprocedural and postprocedural adverse clinical outcomes and overall patient prognosis. As such, the emergent objective understanding of IPTE and its reproducible effects are expected to render IPTE as a clinical end-point in PCI rather than a mere intraprocedural observation.[1][2]

Definition

  • Intraprocedural complications comprise a group of acute ischemic complications that occur during PCI procedures. Although by definition, intraprocedural complications should occur before the end of the PCI procedure; it can however come about before or after stent-placement during PCI. Intraprocedural complications are currently considered an identifiable, relevant, and reproducible clinical endpoint that carries significant prognostic implications of major adverse cardiovascular events.
  • The definitions of intraprocedural complications in both studies were mostly similar; with the exception of “slow-reflow” phenomenon which was mentioned by McEntegart et al. criteria, but not by Pride et al. The definition of new or worsening thrombus formation was based on the increasing size of the thrombus according to McEntegart et al.; while it was based on objective worsening Thrombolysis In Myocardial Infarction (TIMI) flow grade (TFG) from 2-3 to 0-1 according to Pride et al. In both studies, individual etiologies of IPTE were not mutually exclusive events.

Shown below is a table summarizing the complications included in the definition of intraprocedural complications according to Pride et al and McEntegart et al seperately.

Study Intraprocedural complications
Pride et al Abrupt vessel closure
Distal embolization
Loss of side branch
No reflow phenomenon
McEntegart et al Abrupt vessel closure
No reflow
Distal embolization
Intraprocedural stent thrombosis
Slow reflow

Epidemiology and Demographics

  • The overall rate of IPTE is high, currently estimated by several studies to be between 3.5 and 11.4% of all PCI procedures.
  • In 2012, McEntegart et al. performed frame-by-frame analysis for 3,428 patients with [[NSTEMI}non-ST elevation acute coronary syndrome]] (NSTEACS) previously enrolled in the ACUITY trial (Acute Catherterization and Urgent Intervention Triage Strategy). The total incidence of IPTE was 3.5% with varying rates of occurrence among specific etiologies of IPTE. 89.3% of all IPTE occurred at the level of a main branch.[2]
  • Similarly in 2012, Pride et al. evaluated 1,452 high-risk patients with NSTTEAS enrolled in the EARLY ACS trial (Early Glycoprotein IIb/IIIa in Non-ST-Segment Elevation Acute Coronary Syndrome ) who underwent angiographic assessment. Incidence of IPTE was 11.4%.[1]
  • In contrast to McEntegart, the study by Pride et al. included high-risk patients only. High-risk criteria were defined by the authors as having at least two of the following: Ischemic changes on electrocardiography (ECG), elevated cardiac enzyme, advanced age ≥ 60 years or age between 50-59 with documented coronary artery disease, cerebrovascular disease, or peripheral vascular disease. It is uncertain whether the inclusion criteria played a role in the increase of IPTE rates in the study as compared to McEntegart’s findings.[1]

Associated Factors

  • IPTE has been associated with the following factors:
    • Low pre-PCI TIMI flow grade (0-2) and corrected TIMI frame count[1]
    • Low pre-PCI TIMI (0-2)[1]
    • Decreased pre-PCI minimal lumen diameter[1]
    • Increased pre-PCI % stenosis[1]
    • Baseline cardiac biomarker elevation or ST-deviation[2]
  • The use of specific home medications has also not been shown to be significantly associated with IPTE. Pride et al. showed that use of early eptifibatide or bailout eptifibatide was significantly associated with less Normal 0 false false false EN-US X-NONE AR-SA rates of IPTE.

Complications and Prognosis

  • Patients who experience intraprocedural complications are at higher risk of postprocedural 30-day and one year morbidity and mortality. Notably, the number of intraprocedural complications also correlates with the severity of periprocedural outcomes.[1]
  • Shown below is a table demonstrating the significant difference in rates of adverse cardiac events in patients with and without IPTE.[2]
Adverse Cardiac Events In-hospital 30-day 1-year
Patients with IPTE 25.6% 30.6% 37%
Patients without IPTE 6.3% 9.3% 20.5%
  • The risk of death or myocardial infarction (MI), especially Q-wave MI, within 30 days following PCI is four times higher in patients who experience IPTE, even after adjusting for other possible confounding risk factors.[1][2]

Shown below is an image depicting the risk of death or MI in relation with the number of IPTE.

  • The rates of other cardiac thrombotic and non-thrombotic complications are also significantly increased following IPTE in both the periprocedural time frame and after 1 year post-PCI. Associated complications include stent thrombosis, unplanned revascularization, target vessel revascularization (TVR), coronary artery bypass graft (CABG), and non-CABG major bleeding.
  • After evaluating angiographic results post-PCI in patients with vs. without IPTE, IPTE was found to be more significantly associated with a worse post-PCI TIMI flow grade and myocardial perfusion grade. Interestingly, IPTE was found to be a more important correlate with 30-day death and MI than pre-PCI elevation of cardiac enzymes in the NSTEACS patient population. However, the number of patients reported by Pride and colleagues regarding this result was very small; the exact etiology for such findings are yet to be revealed as to whether they are incidental or in fact consequences of prior unrelated cardiac events in these patients.[1]
  • Because IPTE sometimes includes adverse outcomes not accounted for in conventional PCI assessments, the addition of IPTE observations in PCI to already known risk factors of adverse outcome seems to provide a more comprehensive and more realistic prognostic impression for patients undergoing PCI.[1][2][3]

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 Pride YB, Mohanavelu S, Zorkun C, Kunadian V, Giugliano RP, Newby LK; et al. (2012). "Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy". JACC Cardiovasc Interv. 5 (9): 927–35. doi:10.1016/j.jcin.2012.05.007. PMID 22995880.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 McEntegart MB, Kirtane AJ, Cristea E, Brener S, Mehran R, Fahy M; et al. (2012). "Intraprocedural thrombotic events during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes are associated with adverse outcomes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial". J Am Coll Cardiol. 59 (20): 1745–51. doi:10.1016/j.jacc.2012.02.019. PMID 22575311.
  3. Porto, I.; Selvanayagam, JB.; Van Gaal, WJ.; Prati, F.; Cheng, A.; Channon, K.; Neubauer, S.; Banning, AP. (2006). "Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound". Circulation. 114 (7): 662–9. doi:10.1161/CIRCULATIONAHA.105.593210. PMID 16894040. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources